RLAYHealthcare · BiotechnologyThe 14 Wall Street analysts covering Relay Therapeutics, Inc. hold a median 12-month price target of $26 — +30.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Relay Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Issuance (41): The company has been issuing shares or taking on financing, diluting existing holders.
Size (26): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RLAY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +30.9% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | JP Morgan | Maintains | Overweight | $28 → $31 |
| 10 Aug 2026 | Citizens | Maintains | Market Outperform | $21 → $26 |
| 7 Aug 2026 | Barclays | Maintains | Overweight | $27 → $30 |
| 21 July 2026 | Goldman Sachs | Maintains | Buy | $22 → $31 |
| 21 July 2026 | Goldman Sachs | Maintains | Buy | — |
| 16 July 2026 | Canaccord Genuity | Initiates | Buy | $29 |
| 16 July 2026 | Canaccord Genuity | Initiates | Buy | — |
| 8 July 2026 | JP Morgan | Initiates | Overweight | — |
| 26 May 2026 | Guggenheim | Maintains | Buy | — |
| 26 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 May 2026 | Barclays | Maintains | Overweight | — |
| 20 May 2026 | Citizens | Maintains | Market Outperform | — |
| 19 May 2026 | Raymond James | Maintains | Strong Buy | — |
| 29 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Apr 2026 | Citizens | Maintains | Market Outperform | — |
| 28 Apr 2026 | Goldman Sachs | Maintains | Buy | — |
| 28 Apr 2026 | Oppenheimer | Maintains | Outperform | — |
| 28 Apr 2026 | Wells Fargo | Maintains | Overweight | — |
| 14 Apr 2026 | Jones Trading | Initiates | Hold | — |
| 8 Apr 2026 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RLAY appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 94% of US stocks
Cheaper than 2% of US stocks
Cheaper than 23% of US stocks
Cheaper than 85% of US stocks
Higher than 6% of US stocks
Higher than 11% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 25% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Relay Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Relay Therapeutics reported a quarterly loss of $0.41 per share for Q2, in line with the Zacks Consensus Estimate and unchanged from the $0.41 per share loss a year earlier, while its revenue fell short of estimates.
Why it matters — A RLAY watcher would care because the results show earnings met expectations but revenue lagged amid the company's ongoing losses.
Relay Therapeutics reported second-quarter 2026 financial results and corporate updates. The company selected z ovegalisib plus atirmociclib as its go-forward triplet regimen for first-line breast cancer, with a Phase 3 trial in endocrine-sensitive patients expected to initiate in early 2027, subject to regulatory feedback.
Why it matters — The selection of a go-forward triplet regimen and the expected Phase 3 trial initiation mark a key next step for Relay's breast cancer program.
Relay Therapeutics announced it will report its second quarter 2026 financial results and corporate highlights after U.S. markets close on August 6, 2026. The news was shared via a press release on July 30, 2026.
Why it matters — RLAY watchers will look to the August 6 report for updates on the company's clinical programs, financial position, and corporate progress.
Zacks Investment Research reported that Relay Therapeutics (RLAY) has the right combination of key ingredients likely to result in an earnings beat in its upcoming report.
Why it matters — A potential earnings beat could influence investor sentiment around the company's near-term financial performance.
The 14 Wall Street analysts covering Relay Therapeutics, Inc. have a median 12-month price target of $26, with estimates ranging from $20 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Relay Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Relay Therapeutics, Inc. 76 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Relay Therapeutics, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +30.9% from the last close, and Ticker Nerd's factor model ranks Relay Therapeutics, Inc. 76 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Relay Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RLAY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $32 over the next 12 months.
Relay Therapeutics, Inc. returned +485.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Relay Therapeutics Inc. is a clinical-stage precision medicine company focused on transforming drug discovery through its proprietary Dynamo platform, which integrates computational modeling, machine learning, and experimental approaches to target dynamic protein motions for small molecule therapeutics.
The most recent item we track (Zacks Investment Research, 7 Aug 2026): "Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates". Relay Therapeutics reported a quarterly loss of $0.41 per share for Q2, in line with the Zacks Consensus Estimate and unchanged from the $0.41 per share loss a year earlier, while its revenue fell short of estimates.
Relay Therapeutics Inc. is a clinical-stage precision medicine company focused on transforming drug discovery through its proprietary Dynamo platform, which integrates computational modeling, machine learning, and experimental approaches to target dynamic protein motions for small molecule therapeutics. The company specializes in oncology and genetic diseases, with its lead candidate RLY-2608 (zovegalisib), a pan-mutant and isoform-selective PI3Kα inhibitor in clinical development for PI3Kα-mutated HR+/HER2- metastatic breast cancer, solid tumors, and vascular malformations, often in combination with fulvestrant or CDK4/6 inhibitors. Additional programs include an αGal chaperone for Fabry disease, RLY-8161 targeting NRAS-driven tumors, and RLY-1013 as an estrogen receptor alpha degrader. Relay Therapeutics Inc. maintains collaborations with partners like D. E. Shaw Research for computational target analysis, Elevar Therapeutics for lirafugratinib (RLY-4008) in FGFR2-driven cancers, and Pfizer for combination therapies. Founded in 2015 and headquartered in Cambridge, Massachusetts, it plays a key role in advancing precision oncology by addressing challenging protein targets to develop potentially transformative treatments.
CEO Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS · 202 employees · United States · https://www.relaytx.com